Citigroup’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$61.1M Buy
4,226,882
+2,578,335
+156% +$37M 0.03% 566
2025
Q4
$23.5M Buy
1,648,547
+1,536,288
+1,369% +$15.1M 0.01% 1016
2025
Q3
$885K Sell
112,259
-244,016
-68% -$1.74M ﹤0.01% 3240
2025
Q2
$2.04M Sell
356,275
-90,164
-20% -$582K ﹤0.01% 2628
2025
Q1
$3.64M Sell
446,439
-115,894
-21% -$1.07M ﹤0.01% 2209
2024
Q4
$5.3M Buy
562,333
+239,493
+74% +$2.49M ﹤0.01% 1897
2024
Q3
$3.45M Buy
322,840
+176,496
+121% +$1.92M ﹤0.01% 2170
2024
Q2
$1.45M Sell
146,344
-586,792
-80% -$6.02M ﹤0.01% 2608
2024
Q1
$8.64M Buy
733,136
+261,818
+56% +$3.35M 0.01% 1331
2023
Q4
$6.69M Buy
471,318
+96,651
+26% +$1.1M ﹤0.01% 1421
2023
Q3
$4.56M Buy
374,667
+10,303
+3% +$133K ﹤0.01% 1485
2023
Q2
$4.58M Sell
364,364
-231,279
-39% -$2.74M ﹤0.01% 1542
2023
Q1
$6.61M Buy
595,643
+219,224
+58% +$2.7M ﹤0.01% 1346
2022
Q4
$4.6M Sell
376,419
-243,325
-39% -$2.74M ﹤0.01% 1512
2022
Q3
$6.47M Buy
619,744
+32,046
+5% +$357K ﹤0.01% 1394
2022
Q2
$6.31M Buy
587,698
+355,935
+154% +$2.93M ﹤0.01% 1393
2022
Q1
$2.19M Sell
231,763
-277,523
-54% -$2.6M ﹤0.01% 2291
2021
Q4
$5.88M Buy
509,286
+195,405
+62% +$2.18M ﹤0.01% 1708
2021
Q3
$3M Sell
313,881
-191,924
-38% -$1.96M ﹤0.01% 2198
2021
Q2
$4.88M Buy
505,805
+73,010
+17% +$713K ﹤0.01% 1908
2021
Q1
$4.28M Buy
432,795
+335,772
+346% +$5.2M ﹤0.01% 1892
2020
Q4
$2.24M Buy
97,023
+49,001
+102% +$1M ﹤0.01% 2743
2020
Q3
$678K Sell
48,022
-152,035
-76% -$2.22M ﹤0.01% 3589
2020
Q2
$3.02M Sell
200,057
-34,541
-15% -$421K ﹤0.01% 2339
2020
Q1
$2.17M Buy
234,598
+124,622
+113% +$1.18M ﹤0.01% 2396
2019
Q4
$1.07M Sell
109,976
-68,491
-38% -$627K ﹤0.01% 3676
2019
Q3
$1.43M Sell
178,467
-27,741
-13% -$301K ﹤0.01% 3244
2019
Q2
$2.57M Buy
206,208
+187,816
+1,021% +$2.38M ﹤0.01% 2574
2019
Q1
$251K Sell
18,392
-745,496
-98% -$9.11M ﹤0.01% 4874
2018
Q4
$7.32M Sell
763,888
-918,215
-55% -$10.1M 0.01% 1502
2018
Q3
$20.3M Buy
1,682,103
+1,225,986
+269% +$17.1M 0.02% 827
2018
Q2
$7.13M Buy
456,117
+419,714
+1,153% +$6.34M 0.01% 1535
2018
Q1
$547K Buy
36,403
+23,885
+191% +$363K ﹤0.01% 3884
2017
Q4
$180K Sell
12,518
-35,049
-74% -$482K ﹤0.01% 5149
2017
Q3
$718K Sell
47,567
-122,685
-72% -$1.62M ﹤0.01% 3717
2017
Q2
$1.71M Buy
170,252
+130,702
+330% +$1.05M ﹤0.01% 2749
2017
Q1
$282K Sell
39,550
-245,040
-86% -$1.55M ﹤0.01% 4363
2016
Q4
$1.42M Buy
284,590
+255,172
+867% +$1.77M ﹤0.01% 3328
2016
Q3
$218K Buy
29,418
+29,286
+22,186% +$198K ﹤0.01% 4582
2016
Q2
$1K Sell
132
-98,709
-100% -$690K ﹤0.01% 6977
2016
Q1
$835K Buy
98,841
+67,140
+212% +$476K ﹤0.01% 3546
2015
Q4
$308K Sell
31,701
-826,880
-96% -$7.45M ﹤0.01% 4330
2015
Q3
$12M Buy
858,581
+857,328
+68,422% +$13.4M 0.01% 1012
2015
Q2
$18K Sell
1,253
-12,520
-91% -$151K ﹤0.01% 6164
2015
Q1
$150K Sell
13,773
-8,621
-38% -$76K ﹤0.01% 4750
2014
Q4
$186K Buy
22,394
+22,302
+24,241% +$153K ﹤0.01% 4750
2014
Q3
$1K Buy
+92
New +$482 ﹤0.01% 6900
2014
Q2
Sell
-5,771
Closed -$12K 7180
2014
Q1
$12K Sell
5,771
-8,503
-60% -$21.3K ﹤0.01% 6263
2013
Q4
$33K Sell
14,274
-12,064
-46% -$26.5K ﹤0.01% 5929
2013
Q3
$61K Buy
26,338
+26,101
+11,013% +$65.5K ﹤0.01% 5125
2013
Q2
$0 Buy
+237
New +$728 ﹤0.01% 6758

Other funds holding FOLD

Citigroup's FOLD Position: Q1 2026 in Review

Citigroup increased its Amicus Therapeutics (FOLD) stake by 156% in Q1 2026, buying an estimated $37M and bringing the position to 4,226,882 shares worth $61.1M. The position accounts for 0.03% of the portfolio, ranked #566.

Citigroup first reported a position in FOLD in Q2 2013 and has held it in 51 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Citigroup held 4,226,882 shares of Amicus Therapeutics worth $61.1M as of Q1 2026.
  • Citigroup bought 2,578,335 Amicus Therapeutics shares in Q1 2026, an estimated $37M.
  • Amicus Therapeutics made up 0.03% of Citigroup's portfolio in Q1 2026, its #566 holding.
  • Citigroup first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.